BUZZ-贝伦贝格称新一代肥胖症药物将成为即将召开的糖尿病会议的焦点

路透中文

06-11

BUZZ-贝伦贝格称新一代肥胖症药物将成为即将召开的糖尿病会议的焦点

6月11日 - ** 贝伦贝格分析师概述了对6月20-23日美国糖尿病协会会议期间肥胖症药物更新的预期

** 贝伦贝格：诺和诺德NOVOb.CO的CagriSema令人失望后，投资者对肥胖股的兴趣减弱，但该公司可能会通过新数据重振旗鼓

** 增持，礼来LLY.N的orforglipron也受到关注

** 他们说，详细的CagriSema数据可以突出减肥潜力和其他参数，有助于诺和诺德进一步脱离低点

** 今年以来，诺和诺德下跌了 16.7

** 如果orforglipron被证实是安全的，将增加投资者对2026年上市的信心

** 几家公司将提交淀粉样蛋白的数据，如果是积极的，贝伦贝格预计会对西兰ZELA.CO产生积极影响，因为它的风险敞口很高

** 安进公司AMGN.O的MariTide、礼来公司的bimagrumab和罗氏公司ROG.S的CT-388也在贝伦贝格的关注范围之内。

** 贝伦贝格还将关注BrightGene688166.SS的BGM0504、礼来/Innovent的糖尿病药物mazdutide和Terns PharmaTERN.O的口服GLP-1、TERN-601的最新进展。

(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2542390377"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2542390377\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/2542390377?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":false,"pubTime":"2025-06-11 14:39","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2542390377","market":"us","top_or_hot":-1,"title":"BUZZ-贝伦贝格称新一代肥胖症药物将成为即将召开的糖尿病会议的焦点","media":"路透中文","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BUZZ-贝伦贝格称新一代肥胖症药物将成为即将召开的糖尿病会议的焦点</title></head><body><p><span>6月11日</span><span> - </span> ** 贝伦贝格分析师概述了对6月20-23日美国糖尿病协会会议期间肥胖症药物更新的预期</p><p> ** 贝伦贝格：<a href=\"https://laohu8.com/S/NVO\">诺和诺德</a><span>NOVOb.CO</span>的CagriSema令人失望后，投资者对肥胖股的兴趣减弱，但该公司可能会通过新数据重振旗鼓</p><p> ** 增持，<a href=\"https://laohu8.com/S/LLY\">礼来</a><span>LLY.N</span>的orforglipron也受到关注 </p><p> ** 他们说，详细的CagriSema数据可以突出减肥潜力和其他参数，有助于诺和诺德进一步脱离低点</p><p> *<span>* 今年以来，诺和诺德下跌了 16.7 </span></p><p> ** 如果orforglipron被证实是安全的，将增加投资者对2026年上市的信心</p><p> ** 几家公司将提交淀粉样蛋白的数据，如果是积极的，贝伦贝格预计会对西兰<span>ZELA.CO</span>产生积极影响，因为它的风险敞口很高</p><p> ** <a href=\"https://laohu8.com/S/AMGN\">安进</a>公司<span>AMGN.O</span>的MariTide、礼来公司的bimagrumab和罗氏公司<span>ROG.S</span>的CT-388也在贝伦贝格的关注范围之内。</p><p> ** 贝伦贝格还将关注BrightGene<span>688166.SS</span>的BGM0504、礼来/Innovent的糖尿病药物mazdutide和Terns Pharma<span>TERN.O</span>的口服GLP-1、TERN-601的最新进展。</p><p>(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BUZZ-贝伦贝格称新一代肥胖症药物将成为即将召开的糖尿病会议的焦点</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBUZZ-贝伦贝格称新一代肥胖症药物将成为即将召开的糖尿病会议的焦点\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1098195322\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">路透中文 </p>\n<p class=\"h-time\">2025-06-11 14:39</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BUZZ-贝伦贝格称新一代肥胖症药物将成为即将召开的糖尿病会议的焦点</title></head><body><p><span>6月11日</span><span> - </span> ** 贝伦贝格分析师概述了对6月20-23日美国糖尿病协会会议期间肥胖症药物更新的预期</p><p> ** 贝伦贝格：<a href=\"https://laohu8.com/S/NVO\">诺和诺德</a><span>NOVOb.CO</span>的CagriSema令人失望后，投资者对肥胖股的兴趣减弱，但该公司可能会通过新数据重振旗鼓</p><p> ** 增持，<a href=\"https://laohu8.com/S/LLY\">礼来</a><span>LLY.N</span>的orforglipron也受到关注 </p><p> ** 他们说，详细的CagriSema数据可以突出减肥潜力和其他参数，有助于诺和诺德进一步脱离低点</p><p> *<span>* 今年以来，诺和诺德下跌了 16.7 </span></p><p> ** 如果orforglipron被证实是安全的，将增加投资者对2026年上市的信心</p><p> ** 几家公司将提交淀粉样蛋白的数据，如果是积极的，贝伦贝格预计会对西兰<span>ZELA.CO</span>产生积极影响，因为它的风险敞口很高</p><p> ** <a href=\"https://laohu8.com/S/AMGN\">安进</a>公司<span>AMGN.O</span>的MariTide、礼来公司的bimagrumab和罗氏公司<span>ROG.S</span>的CT-388也在贝伦贝格的关注范围之内。</p><p> ** 贝伦贝格还将关注BrightGene<span>688166.SS</span>的BGM0504、礼来/Innovent的糖尿病药物mazdutide和Terns Pharma<span>TERN.O</span>的口服GLP-1、TERN-601的最新进展。</p><p>(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"IE00BJLML261.HKD","symbol_name":"HSBC GLOBAL EQUITY INDEX \"HCH\" (HKD) ACC","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250611:nL4S3SE0GU:1","article_id":"2542390377","we_media_id":"1098195322","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2542390377","pubTimestamp":1749623996,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"路透中文","introduction":"路透中文","home_visible":1,"id":"1098195322","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"zh","relate_stocks":{"688166":"博瑞医药","IE00BJLML261.HKD":"HSBC GLOBAL EQUITY INDEX \"HCH\" (HKD) ACC","LU0109394709.USD":"富兰克林生物科技新领域基金A (acc)","BK0239":"医药制造","LU2211815571.USD":"ALLIANZ POSITIVE CHANGE \"AT\" (USD) ACC","LU1868837136.USD":"CT (LUX) I AMERICAN \"8\" (USD) ACC","LU2264538146.SGD":"Fullerton Lux Funds - Global Absolute Alpha A Acc SGD","LU2361044949.HKD":"WELLINGTON US QUALITY GROWTH \"A\" (HKD) ACC","LU2471134879.HKD":"INVESCO GLOBAL EQUITY INCOME ADVANTAGE \"A\" (HKD) INC","LU0097036916.USD":"贝莱德美国增长A2 USD","LU0466842654.USD":"HSBC ISLAMIC GLOBAL EQUITY INDEX \"A\" (USD) ACC","LU2236285917.USD":"ALLIANZ GLOBAL INCOME \"AMG\" (USD) INC","IE00B1BXHZ80.USD":"Legg Mason ClearBridge - US Appreciation A Acc USD","LU0672654240.SGD":"FTIF - Franklin US Opportunities A Acc SGD-H1","LU1720051017.SGD":"Allianz Global Artificial Intelligence AT Acc H2-SGD","LU2417539215.USD":"ALLIANZ GLOBAL INCOME \"AMF\" (USD) INC","LU0198837287.USD":"UBS (LUX) EQUITY SICAV - USA GROWTH \"P\" (USD) ACC","LU0323591593.USD":"SCHRODER ISF QEP GLOBAL QUALITY \"A\" (USD) ACC","LU1548497426.USD":"安联环球人工智能AT Acc","LU2552382215.SGD":"WELLINGTON US BRAND POWER \"A\" (SGDHDG) ACC","LU2456880835.USD":"ALLIANZ GLOBAL INCOME \"AT\" (USD) ACC","LU2602419157.SGD":"HSBC ISLAMIC GLOBAL EQUITY INDEX \"AC\" (SGD) ACC","LU1551013425.SGD":"Allianz Income and Growth Cl AMg2 DIS H2-SGD","LU0354030438.USD":"富国美国大盘成长基金Cl A Acc","SG9999001440.SGD":"United Global Dividend Equity Fund A SGD Dist","LU2462157665.USD":"ALLIANZ GLOBAL INCOME \"A\" (USD) INC","LU2237443895.HKD":"abrdn SICAV I -  GLOBAL DYNAMIC DIVIDEND \"A\" (HKD) ACC","LU1571399168.USD":"ALLSPRING GLOBAL LONG/SHORT EQUITY \"IP\" (USD) ACC","LU0889565916.HKD":"FRANKLIN BIOTECHNOLOGY DISCOVERY \"A\" (HKD) ACC","LU1232071149.USD":"AZ FUND 1 GLOBAL GROWTH SELECTOR \"AAZ\" (USDHDG) ACC","AMGN":"安进","LU1720051108.HKD":"ALLIANZ GLOBAL ARTIFICIAL INTELLIGENCE \"AT\" (HKD) ACC","01801":"信达生物","BK4007":"制药","SG9999014914.USD":"UNITED GLOBAL QUALITY GROWTH (USDHDG) INC","LU2089984988.USD":"MANULIFE GF HEALTHCARE \"AA\" (USD) ACC","LU2357305700.SGD":"Allianz Global Artificial Intelligence ET H2-SGD","LU1267930730.SGD":"富兰克林美国机遇基金AS Acc SGD (CPF)","LU2112291526.USD":"BGF WORLD HEALTHSCIENCE \"A4\" (USD) INC","LU0238689110.USD":"贝莱德环球动力股票基金","SGXZ99366536.SGD":"United Global Innovation A Acc SGD-H","LU1057294990.SGD":"Blackrock World Healthscience A2 SGD-H","LU2237443382.USD":"Aberdeen Standard SICAV I - Global Dynamic Dividend A MIncA USD","LU0256863902.USD":"ALLIANZ US EQUITY \"AT\" (USD) ACC","LU0266013472.USD":"AXA WF - Framlington Longevity Economy A Cap USD","TERN":"Terns Pharmaceuticals, Inc.","LU1623119135.USD":"Natixis Mirova Global Sustainable Equity R-NPF/A USD","BK4588":"碎股","IE00BJT1NW94.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (SGDHDG) ACC"},"translate_title":"BUZZ-Berenberg says new generation of obesity drugs will be the focus of upcoming diabetes conference","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"688166":0.9,"01801":0.9,"AMGN":0.9,"TERN":0.9},"content_text":"BUZZ-贝伦贝格称新一代肥胖症药物将成为即将召开的糖尿病会议的焦点6月11日 -  ** 贝伦贝格分析师概述了对6月20-23日美国糖尿病协会会议期间肥胖症药物更新的预期 ** 贝伦贝格：诺和诺德NOVOb.CO的CagriSema令人失望后，投资者对肥胖股的兴趣减弱，但该公司可能会通过新数据重振旗鼓 ** 增持，礼来LLY.N的orforglipron也受到关注  ** 他们说，详细的CagriSema数据可以突出减肥潜力和其他参数，有助于诺和诺德进一步脱离低点 ** 今年以来，诺和诺德下跌了 16.7  ** 如果orforglipron被证实是安全的，将增加投资者对2026年上市的信心 ** 几家公司将提交淀粉样蛋白的数据，如果是积极的，贝伦贝格预计会对西兰ZELA.CO产生积极影响，因为它的风险敞口很高 ** 安进公司AMGN.O的MariTide、礼来公司的bimagrumab和罗氏公司ROG.S的CT-388也在贝伦贝格的关注范围之内。 ** 贝伦贝格还将关注BrightGene688166.SS的BGM0504、礼来/Innovent的糖尿病药物mazdutide和Terns PharmaTERN.O的口服GLP-1、TERN-601的最新进展。(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"code":"91000000","status":"200"}}}